1-氰基-1-<1-(3-甲基)哌啶子基>环己烷 | 106652-61-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-氰基-1-<1-(3-甲基)哌啶子基>环己烷
• 英文名称: 1-cyano-1-<1-(3-methyl)piperidino>cyclohexane
• 英文别名: 1-(3-Methylpiperidin-1-yl)cyclohexane-1-carbonitrile
• CAS: 106652-61-3
• 化学式: C₁₃H₂₂N₂
• 分子量: 206.331
• InChiKey: CSVMGBRNMMXDFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-碘-苯并[b]噻吩 、 1-氰基-1-<1-(3-甲基)哌啶子基>环己烷 在 magnesium 作用下， 生成 (+/-)-1-<1-(2-benzothiophenyl)cyclohexyl>-3-methylpiperidine
  参考文献：
  名称：

  Arylcyclohexylamines derived from BTCP are potent indirect catecholamine agonists

  摘要：

  N-[1-(2-Benzo[b]thiophenyl)cyclohexyl]piperidine (BTCP)-related molecules were prepared by means of chemical modulation of the 3 rings which constitute this dopamine (DA) and norepinephrine (NE) uptake inhibitor. Tested in vitro (binding to the DA uptake complex and to the PCP receptor sites, inhibition of the synaptosomal uptake of DA and NE) and in vivo (locomotor activity in mice) these molecules showed good homogeneity of action. The newly prepared structures, although formally related to the phencyclidine (PCP) structural model, no longer display significant affinity for the PCP receptor. These compounds behave like a new series of indirect potent stimulants of the dopaminergic and noradrenergic systems leading to potential antidepressive compounds.

  DOI：

  10.1016/0223-5234(93)90124-w
• 作为产物：
  描述：

  丙酮氰醇 、 3-甲基哌啶 在 2,4-滴二甲胺盐 、 magnesium sulfate 作用下， 以 环己酮 为溶剂， 生成 1-氰基-1-<1-(3-甲基)哌啶子基>环己烷
  参考文献：
  名称：

  Substituted cyclic amines and pharmaceutical composition containing them

  摘要：

  该发明涉及取代芳胺和杂芳胺，它们的制备过程以及含有它们的药物组合物。所述取代胺符合以下公式：##STR1## 其中R.sup.1和R.sup.2是可选地取代的烷基基团，或者与N形成可选地取代的哌嗪或哌啶环，R.sup.3和R.sup.4代表氢原子或有机基团，Y代表CR.sup.6或N，R.sup.5是可选地取代的苯并噻吩基、苯并呋喃基或萘基。这些胺可以用于治疗神经抑郁或刺激警觉的药物组合物中。

  公开号：

  US05248686A1

文献信息

• PCP receptor and dopamine uptake sites are discriminated by chiral TCP and BTCP derivatives of opposite configuration
  作者：E Coderc、P Cerruti、JF Rouayrenc、JM Kamenka、J Vignon

  DOI：10.1016/0223-5234(96)88257-2

  日期：1995.1

  3-Methylpiperidine derivatives of 1-[1-(2-thienyl)cyclohexyl]piperidine (TCP) and 1-[1-(2-benzo[b]thiophenyl)cyclohexyl]piperidine (BTCP) were obtained in their racemic and homochiral forms. They have been tested for their affinity for the PCP receptor labeled with [H-3]TCP and for the dopamine transporter labeled with [H-3]BTCP. The homochiral TCP derivative (+)-R displayed a very high affinity (5.2 nM) and selectivity for the PCP receptor. In contrast, the homochiral BTCP derivative (-)-S, therefore of opposite configuration, displayed a very high affinity (3.5 nM) and selectivity for the dopamine transporter.
• US5248686A
  申请人：——

  公开号：US5248686A

  公开（公告）日：1993-09-28
• Arylcyclohexylamines derived from BTCP are potent indirect catecholamine agonists
  作者：AT Ilagouma、T Maurice、D Duterte-Boucher、E Coderc、J Vignon、J Costentin、JM Kamenka

  DOI：10.1016/0223-5234(93)90124-w

  日期：1993.1

  N-[1-(2-Benzo[b]thiophenyl)cyclohexyl]piperidine (BTCP)-related molecules were prepared by means of chemical modulation of the 3 rings which constitute this dopamine (DA) and norepinephrine (NE) uptake inhibitor. Tested in vitro (binding to the DA uptake complex and to the PCP receptor sites, inhibition of the synaptosomal uptake of DA and NE) and in vivo (locomotor activity in mice) these molecules showed good homogeneity of action. The newly prepared structures, although formally related to the phencyclidine (PCP) structural model, no longer display significant affinity for the PCP receptor. These compounds behave like a new series of indirect potent stimulants of the dopaminergic and noradrenergic systems leading to potential antidepressive compounds.
• Substituted cyclic amines and pharmaceutical composition containing them
  申请人：Centre National de la Recherche Scientifique

  公开号：US05248686A1

  公开（公告）日：1993-09-28

  The invention relates to substituted arylamines and heteroarylamines, their preparation process and the pharmaceutical composition containing them. Said substituted amine is in accordance with the formula: ##STR1## in which R.sup.1 and R.sup.2 are optionally substituted alkyl radicals or form with N an optionally substituted piperazine or piperidine cycle, R.sup.3 and R.sup.4 represent a hydrogen atom or an organic radical, Y represents CR.sup.6 or N and R.sup.5 is an optionally substituted benzothiophenyl, benzofuranyl or naphthyl radical. These amines can be used in pharmaceutical compositions for the treatment of nervous depression or for stimulating vigilance.

  该发明涉及取代芳胺和杂芳胺，它们的制备过程以及含有它们的药物组合物。所述取代胺符合以下公式：##STR1## 其中R.sup.1和R.sup.2是可选地取代的烷基基团，或者与N形成可选地取代的哌嗪或哌啶环，R.sup.3和R.sup.4代表氢原子或有机基团，Y代表CR.sup.6或N，R.sup.5是可选地取代的苯并噻吩基、苯并呋喃基或萘基。这些胺可以用于治疗神经抑郁或刺激警觉的药物组合物中。